Phio Pharmaceuticals Corp. rose 1.26% in premarket trading, with the company announcing the closing of its public offering of 10,000,000 shares of its common stock at $0.10 per share. The gross proceeds from the offering were used to fund the company's immuno-oncology therapeutics development based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform.
Comments
No comments yet